ACASTI PHARMA INC. (NASDAQ:ACST) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | Press Release issued by Acasti Pharma Inc. on September 16, 2020 |
Acasti Pharma Inc. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1 Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer LAVAL,…
To view the full exhibit click here
About ACASTI PHARMA INC. (NASDAQ:ACST)
Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company’s prescription drug candidate is CaPre, which is being developed for the treatment of severe hypertriglyceridemia and eventually mild to moderate hypertriglyceridemia. The Company’s ONEMIA has a natural health product status in Canada, and it is commercialized as a medical food in the United States. Onemia is a purified omega-3 phospholipids concentrate derived from krill oil with lower levels of phospholipids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) content than CaPre.